SUPERNUS PHARMACEUTICALS, INC. (SUPN) Total liabilities 2016–2025
SUPERNUS PHARMACEUTICALS, INC. (SUPN) total liabilities at each fiscal year-end, per SEC filings.
$390.9MFY2025 · since FY2016: $117.8M → $390.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $390.9M | +17.6% |
| FY2024 | $332.3M | -6.7% |
| FY2023 | $356.2M | -56.4% |
| FY2022 | $816.3M | -6.5% |
| FY2021 | $873.3M | +15.0% |
| FY2020 | $759.2M | +34.4% |
| FY2019 | $564.9M | +7.6% |
| FY2018 | $524.8M | +234.3% |
| FY2017 | $157.0M | +33.2% |
| FY2016 | $117.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice